Source - BF
Equity research analysts at finnCap reckon AIM listed ANGLE (LON:ANG) is set to cash in on its "ability to position Parsortix where there is a clear and differentiated clinical need in an addressable market of c.£8bn".

In its initiation note, the house broker added: "Launched into the research market in FY 2016, Parsortix is gaining traction in leading cancer centres and with eminent KOLs, which should accelerate if, as we expect, FDA clearance is achieved in late 2018/early 2019."

finnCap set a target price of 100 pence on the stock, almost 3 times their current value.

At 3:26pm: (LON:ANG) Angling Direct Plc Ord 1p share price was 0p at 83p